Cargando…
Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019?
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309524/ https://www.ncbi.nlm.nih.gov/pubmed/32527763 http://dx.doi.org/10.1212/NXI.0000000000000811 |
| _version_ | 1783549224630091776 |
|---|---|
| author | Maguire, Cole Frohman, Teresa Zamvil, Scott S. Frohman, Elliot Melamed, Esther |
| author_facet | Maguire, Cole Frohman, Teresa Zamvil, Scott S. Frohman, Elliot Melamed, Esther |
| author_sort | Maguire, Cole |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7309524 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-73095242020-07-06 Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? Maguire, Cole Frohman, Teresa Zamvil, Scott S. Frohman, Elliot Melamed, Esther Neurol Neuroimmunol Neuroinflamm Clinical/Scientific Notes Lippincott Williams & Wilkins 2020-06-11 /pmc/articles/PMC7309524/ /pubmed/32527763 http://dx.doi.org/10.1212/NXI.0000000000000811 Text en Copyright © 2020 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work, provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
| spellingShingle | Clinical/Scientific Notes Maguire, Cole Frohman, Teresa Zamvil, Scott S. Frohman, Elliot Melamed, Esther Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? |
| title | Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? |
| title_full | Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? |
| title_fullStr | Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? |
| title_full_unstemmed | Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? |
| title_short | Should interferons take front stage as an essential MS disease-modifying therapy in the era of coronavirus disease 2019? |
| title_sort | should interferons take front stage as an essential ms disease-modifying therapy in the era of coronavirus disease 2019? |
| topic | Clinical/Scientific Notes |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7309524/ https://www.ncbi.nlm.nih.gov/pubmed/32527763 http://dx.doi.org/10.1212/NXI.0000000000000811 |
| work_keys_str_mv | AT maguirecole shouldinterferonstakefrontstageasanessentialmsdiseasemodifyingtherapyintheeraofcoronavirusdisease2019 AT frohmanteresa shouldinterferonstakefrontstageasanessentialmsdiseasemodifyingtherapyintheeraofcoronavirusdisease2019 AT zamvilscotts shouldinterferonstakefrontstageasanessentialmsdiseasemodifyingtherapyintheeraofcoronavirusdisease2019 AT frohmanelliot shouldinterferonstakefrontstageasanessentialmsdiseasemodifyingtherapyintheeraofcoronavirusdisease2019 AT melamedesther shouldinterferonstakefrontstageasanessentialmsdiseasemodifyingtherapyintheeraofcoronavirusdisease2019 |